Neonatal Persistent Pulmonary Hypertension: Inhaled Nitric Oxide Use
Neonatal persistent pulmonary hypertension (PPHN) is a failure of the normal circulatory transition after birth. Pulmonary vascular resistance remains abnormally high, limiting pulmonary blood flow and allowing right-to-left shunting through the ductus arteriosus or foramen ovale. The result is hypoxemia that may be severe, labile, and disproportionate to the apparent lung disease.
Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator used to reduce pulmonary vascular resistance and improve oxygenation in carefully selected newborns. Its value is greatest when pulmonary hypertension is a major contributor to respiratory failure, rather than when hypoxemia results primarily from unrecognized congenital heart disease, severe parenchymal lung injury, or inadequate ventilation.
Clinical decisions should combine echocardiography, oxygenation measurements, lung recruitment, hemodynamic assessment, and the infant’s gestational age. The scientific focus associated with the FAOPS 2020 website included perinatal and neonatal medicine, fields in which prompt recognition and disciplined escalation remain central to safer care.
Understanding The Pulmonary Vascular Transition
Before birth, the placenta provides oxygen and the fetal lungs receive relatively little blood flow. Pulmonary arterioles are constricted, while the ductus arteriosus and foramen ovale direct blood away from the lungs. At birth, lung aeration, increased oxygen tension, and removal of placental vascular mediators should lower pulmonary vascular resistance rapidly.
PPHN develops when that fall is delayed or reversed. Meconium aspiration, respiratory distress syndrome, pneumonia, sepsis, birth asphyxia, pulmonary hypoplasia, and congenital diaphragmatic hernia can all contribute. Some infants have structurally remodeled pulmonary arteries, while others have predominantly reactive vasoconstriction. These mechanisms influence how strongly an infant responds to oxygen, ventilation, and iNO.
The clinical picture often includes marked preductal and postductal oxygen saturation differences, differential cyanosis, respiratory distress, and fluctuating oxygenation. However, PPHN can coexist with left ventricular dysfunction, right ventricular failure, or structural heart disease. A preductal and postductal saturation comparison is useful, but it cannot replace echocardiography.
When Inhaled Nitric Oxide Is Appropriate
iNO diffuses across the alveolar-capillary membrane into adjacent pulmonary vascular smooth muscle. It activates guanylate cyclase, increases cyclic guanosine monophosphate, and produces selective dilation of vessels serving ventilated lung units. Because it is rapidly inactivated by hemoglobin, its systemic vasodilator effect is usually limited.
The strongest evidence supports iNO in term and near-term infants with hypoxic respiratory failure and echocardiographic or clinical evidence of pulmonary hypertension after lung expansion and ventilation have been optimized. Many neonatal protocols consider treatment when the oxygenation index reaches approximately 15–25, although the threshold varies with local policy, disease severity, and the speed of deterioration.
Preterm infants require a more individualized decision. Routine iNO for all premature infants with respiratory failure has not consistently improved survival or reduced bronchopulmonary dysplasia. A neonatologist may still consider rescue treatment when there is documented pulmonary hypertension, pulmonary hypoplasia, prolonged rupture of membranes, or another physiologically compelling indication.
Echocardiography should assess shunt direction, right ventricular function, pulmonary artery pressure estimates, ductal flow, left ventricular performance, and possible structural heart disease. iNO can be ineffective or harmful when pulmonary venous obstruction, severe left-sided dysfunction, or a ductal-dependent cardiac lesion is the main cause of low oxygenation.
Initiating And Monitoring Treatment
Before starting iNO, clinicians should optimize lung recruitment without causing excessive airway pressure. This may include appropriate continuous positive airway pressure, conventional ventilation, high-frequency ventilation, surfactant for surfactant-deficient disease, and correction of acidosis, hypothermia, anemia, hypoglycemia, and systemic hypotension. A poorly recruited lung limits delivery of nitric oxide to the pulmonary circulation.
A commonly used starting dose is 20 parts per million for term or near-term infants. Oxygenation should be reassessed clinically and with blood gases or pulse oximetry within 30–60 minutes. A meaningful response generally includes a sustained improvement in preductal oxygenation, reduced oxygen requirement, improved oxygenation index, or better echocardiographic evidence of pulmonary blood flow.
The oxygenation index is calculated as:
OI = FiO₂ × mean airway pressure × 100 ÷ PaO₂
It can help track severity and treatment response, but it should not be interpreted in isolation. A rising OI despite adequate ventilation suggests that the infant may need an alternative diagnosis, additional cardiovascular support, or extracorporeal membrane oxygenation (ECMO) assessment.
The delivery system must be calibrated and monitored for nitric oxide and nitrogen dioxide concentrations. Methemoglobin should be checked after treatment begins and periodically during prolonged therapy. Blood pressure, urine output, lactate, right and left ventricular performance, and serial blood gases provide important information about whether oxygenation gains are translating into effective systemic perfusion.
Matching Therapy To The Clinical Picture
The following comparison can help distinguish common treatment situations. It is a framework for clinical reasoning rather than a substitute for echocardiography or an institutional neonatal protocol.
| Clinical situation | Likely role of iNO | Essential considerations |
|---|---|---|
| Term infant with PPHN and adequate lung recruitment | Appropriate rescue or targeted therapy | Confirm pulmonary hypertension, assess response within 30–60 minutes |
| Meconium aspiration with severe hypoxemia | Often beneficial | Combine with lung recruitment, surfactant when indicated, and infection evaluation |
| Respiratory distress syndrome in an extremely preterm infant | Not routine | Consider only with documented pulmonary hypertension or a specific physiologic indication |
| Congenital diaphragmatic hernia | Selective rescue use | Evaluate ventricular function and pulmonary hypoplasia; response may be limited |
| Suspected cyanotic congenital heart disease | Do not start reflexively | Obtain urgent echocardiography; iNO may alter ductal and pulmonary blood flow in undesirable ways |
| Persistent hypoxemia despite optimized ventilation and iNO | Reassess and escalate | Review diagnosis, cardiac function, dose delivery, and ECMO eligibility |
A rapid rise in oxygen saturation after iNO supports a pulmonary vasoconstrictive component, but lack of response does not prove that PPHN is absent. Severe parenchymal disease, pulmonary hypoplasia, ventricular dysfunction, inadequate alveolar ventilation, or technical delivery problems may prevent improvement.
A response can also be transient. As oxygenation improves, clinicians should continue addressing the initiating illness rather than treating the monitor value alone. The infant may need antibiotics, surfactant, fluid restriction, inotropes, blood products, or ventilator adjustment according to the underlying condition.
Safety, Weaning, And Escalation
Nitric oxide inhibits platelet aggregation to some degree and may increase bleeding risk in vulnerable infants. This matters when there is pulmonary hemorrhage, coagulopathy, recent invasive procedures, or severe thrombocytopenia. A focused review of neonatal thrombocytopenia causes can provide useful background when low platelet counts complicate respiratory and cardiovascular management.
Abrupt discontinuation can cause rebound pulmonary hypertension and sudden deterioration. Once oxygenation is stable, iNO is usually reduced in stepwise fashion, often from 20 to 10, then 5, and subsequently smaller doses. The infant should be observed after each reduction. If oxygenation worsens, return to the previous effective dose and investigate lung recruitment, ventricular function, infection, and shunt physiology.
If there is little or no improvement after an adequate trial, continuing iNO indefinitely can delay more appropriate treatment. Possible next steps include optimizing ventilation, treating sepsis or acidosis, using vasoactive support, considering sildenafil or another pulmonary vasodilator in selected settings, and contacting an ECMO center. Sildenafil may help facilitate iNO weaning in some cases, but neonatal evidence and dosing practices vary.
Care Beyond Pulmonary Vasodilation
PPHN is a whole-patient disorder. Hypoxemia, acidosis, hypothermia, infection, poor cardiac output, and excessive stimulation can intensify pulmonary vasoconstriction. A calm environment, careful analgesia or sedation when clinically appropriate, thermal stability, and correction of metabolic abnormalities support the pulmonary circulation while definitive treatment proceeds.
Nutrition and antenatal factors also belong in the wider perinatal assessment. Maternal disease, placental insufficiency, fetal growth restriction, and inflammatory exposures may shape neonatal adaptation. Broader perinatal resources, including discussion of omega-3 fatty acids, can help place neonatal respiratory disease within the longer continuum of fetal and infant development, although nutritional information does not replace acute PPHN treatment.
Survivors need follow-up for neurodevelopment, hearing, vision, growth, chronic lung disease, and recurrent respiratory symptoms. The severity and duration of hypoxemia, associated neurologic injury, mechanical ventilation, and the underlying diagnosis all affect prognosis. Families benefit from clear explanations that iNO treats pulmonary vascular tone; it does not correct every cause of neonatal respiratory failure.
Practical Recommendations For Bedside Teams
- Confirm that hypoxemia is compatible with PPHN and obtain echocardiographic assessment whenever possible.
- Optimize lung recruitment, ventilation, oxygen delivery, blood pressure, temperature, glucose, and acid-base status before judging iNO response.
- Use a protocolized starting dose, commonly 20 ppm in term or near-term infants, with early reassessment of oxygenation and hemodynamics.
- Monitor methemoglobin, nitrogen dioxide exposure, platelet and bleeding risks, blood gases, ventricular function, and oxygenation index.
- Wean gradually after sustained improvement, and escalate promptly to specialist consultation or ECMO evaluation when severe hypoxemia persists.
Turning Evidence Into Action
Inhaled nitric oxide is most effective when it is used as one component of a diagnostic and physiologic strategy. The central questions are whether pulmonary vascular resistance is truly driving the infant’s hypoxemia, whether the lungs are adequately recruited, and whether cardiac performance can tolerate the changing circulation.
Use these principles alongside local neonatal protocols, specialist echocardiography, and timely transport pathways. Early recognition, measured treatment, and prompt escalation can give infants with severe pulmonary hypertension the best opportunity for stable oxygenation and recovery.
